Highest-materiality recent filing
Novavax Q1 revenue $140M, net loss $9M; Pfizer Matrix-M deal adds $30M upfront
Total revenue $140M, down 79% YoY; prior-year included $603M non-cash APA close-out.
Novavax Q4 net income $18M, full-year profit $440M; Pfizer Matrix-M license deal
Q4 2025 revenue $147M (+67% YoY); net income $18M vs $81M loss in Q4 2024.
Novavax licenses Matrix-M adjuvant to Pfizer for up to $500M milestones plus royalties
Upfront payment of $30M in Q1 2026; eligible for up to $500M in milestones ($70M development, $180M sales per field).
Novavax Q3 net loss $202M, revenue down to $70M; raises FY2025 revenue guidance
Total revenue $70M, down 18% YoY from $85M; product sales (Nuvaxovid) $0 vs $38M.
Assignment fee $15M, parcel sale $20M, asset sale $24.8M; total $59.8M from AstraZeneca.
Novavax completes Nuvaxovid EU marketing authorization transfer to Sanofi; triggers $25M milestone
European Commission approved transfer of Nuvaxovid EU marketing authorization from Novavax CZ to Sanofi Winthrop Industrie.
FDA approves Novavax's Nuvaxovid 2025-2026 COVID-19 vaccine for high-risk populations
Approved for adults 65+ and high-risk individuals 12-64; only protein-based non-mRNA COVID-19 vaccine available in U.S. for 2025-2026 season.
Novavax issues $225M 4.625% convertible notes due 2031, exchanges $148.7M of 2027 notes
Issued $225M principal of 4.625% Convertible Senior Notes due 2031; initial conversion price ~$11.14 (27.5% premium).
Novavax issues $225M in 4.625% convertible notes due 2031, refinancing 2027 notes
Issued $225M of 4.625% Convertible Senior Notes due 2031; exchanged ~$148.7M of 2027 notes and raised ~$49.7M new cash.
Novavax Q2 revenue $239M; net income $107M; $175M Sanofi milestone from FDA BLA approval
Total revenue of $239M, down 42% YoY, includes $175M milestone from Nuvaxovid BLA approval.
Novavax Phase 3 CIC & flu vaccine candidates show robust immune responses, well tolerated
COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine candidates induced 2.4-5.7-fold immune responses over baseline.
Novavax eliminates COO role; John Trizzino to depart June 20, 2025
COO position eliminated; John Trizzino's employment terminated effective June 20, 2025.
Novavax receives FDA approval for Nuvaxovid COVID-19 vaccine; triggers $175M Sanofi milestone
FDA approves BLA for Nuvaxovid for COVID-19 in adults 65+ and high-risk individuals 12-64.
determined to eliminate the position of Chief Operating Officer, and terminate the employment of John Trizzino with the Company effective as of June 20, 2025.
Max materiality 0.85 · Median 0.75 · Most common event other_material